Investor Ideas Adds New #Nasdaq IPOs in #Biotech (Nasdaq: $ALLO, $EQ, $GH, $KOD, $PRNB, $YMAB) & Newly Listed #CSE Stocks
CSE-Listed Stocks in #Mining, #Energy and #Nanotech (CSE: $CRES, $DLRY, $KAL, $SENS, $SONA)
Point Roberts, WA and Delta, BC - October 26, 2018 (Investorideas.com Newswire) Investorideas.com, a global news source and leading investor resource announces this week’s additions to its global stock directories in biotech, mining, energy and nanotech.
Investorideas.com is a go- to destination for retail investors and tracks companies in high-profile trading sectors and makes ongoing additions to its stock directories for its followers and members . (https://www.investorideas.com/membership/)
New biotech companies are all recent Nasdaq IPO's and include biotech, oncology, biopharma and life sciences companies providing treatments for cancer, autoimmune and ophthalmic diseases.
The latest mining companies are all CSE-Listed and operate in Canada, while the newest energy company (also CSE-Listed), is a leading solutions provider to various sectors including the oil and gas industry.
Finally, the newest nanotech company Sona Nanotech Inc. (CSE: SONA), also crosses over into the biotech (life sciences) sector with their rod-shaped gold nanoparticles which are used in multiplex diagnostic testing platforms.
New Biotech Companies:
ALLOGENE THERAPEUTICS, INC. (NasdaqGS: ALLO) with headquarters in South San Francisco, is a clinical stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T-cell (AlloCAR T™) therapies for cancer.
EQUILLIUM, INC (NasdaqGM: EQ) is a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium's initial product candidate, EQ001 (itolizumab), is a clinical-stage, first-in-class monocolonal antibody that selectively targets the novel immune checkpoint receptor CD6 and is designed to modulate T cells that drive immuno-inflammation. Itolizumab is a clinically-validated therapeutic with a favorable safety and tolerability profile. Equillium plans to advance EQ001 into clinical development in multiple indications of high unmet medical need and believes EQ001 has the potential to be a best-in-class disease modifying therapeutic.
GUARDANT HEALTH, INC. (NasdaqGS: GH) is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Its Guardant Health Oncology Platform is designed to leverage its capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. In pursuit of its goal to manage cancer across all stages of the disease, Guardant Health has launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its LUNAR development programs for recurrence and early detection. Since its launch in 2014, Guardant360 has been used by more than 5,000 oncologists, over 40 biopharmaceutical companies and all 27 of the National Comprehensive Cancer Network centers.
KODIAK SCIENCES INC. (NasdaqGM: KOD) is a clinical stage company developing innovative therapeutics to treat high prevalence ophthalmic diseases. We aspire to global leadership in ophthalmology through internal focus and by aggregating top talent, technologies, discoveries and ideas. Our Antibody Biopolymer Conjugate, or ABC Platform™, merges the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. In addition to its lead product candidate, KSI-301, a potential best in class molecule for age-related macular degeneration and diabetic retinopathy, Kodiak has leveraged its ABC Platform™ to build a pipeline of product candidates in various stages of development including KSI-501, a dual inhibitor ABC for the treatment of neovascular retinal diseases such as wet AMD and diabetic retinopathy. Kodiak is based in Palo Alto, CA.
PRINCIPIA BIOPHARMA INC. (NasdaqGS:PRNB) is a clinical-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology. Principia's proprietary Tailored Covalency® platform enables Principia to design and develop reversible and irreversible covalent, small molecule inhibitors with potencies and selectivities that have the potential to rival those of injectable biologics, yet maintain the convenience of a pill. PRN1008, a reversible covalent BTK inhibitor, is being evaluated in a Phase 2 clinical trial in patients with pemphigus, an orphan autoimmune disease, and in a Phase 2 clinical trial in patients with ITP, a rare hematological disease. PRN2246, a covalent BTK inhibitor which crosses the blood-brain barrier, has completed a Phase 1 clinical trial in healthy volunteers, and has been partnered with Sanofi for development in multiple sclerosis and, potentially, for other diseases of the CNS. PRN1371, a covalent inhibitor of Fibroblast Growth Factor Receptor (FGFR), is being evaluated in a Phase 1 trial in patients with solid tumors.
Y-mAbs THERAPEUTICS, INC. (NasdaqGS: YMAB) is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The Company has a broad and advanced product pipeline, including two pivotal-stage product candidates-naxitamab and omburtamab-which target tumors that express GD2 and B7-H3, respectively.
New Mining Companies:
Crest Resources Inc. (CSE: CRES) is engaged in the business of mineral exploration and the acquisition of mineral property assets in Canada. Its objective is to locate and develop economic precious and base metal properties of merit and to conduct its exploration program on the Red Metal Ridge Property. The Red Metal Ridge Property is comprised of six contiguous mineral titles covering an area of 1381.50 hectares, located 74 kilometres northwest of the town of Campbell River and 12 kilometres southwest of the town of Sayward on Vancouver Island, British Columbia, Canada.
Delrey Metals Corp. (CSE:DLRY) is an exploration stage mineral resources company whose principal business activities include acquiring, exploring and evaluating strategic energy mineral properties
Kal Minerals Corp. (CSE: KAL) is a Canadian junior mineral exploration company with a specific focus on properties in the New Westminster Mining Division of British Columbia, Canada. The Company's sole property, the Jack White Property, is comprised of four mineral tenures covering approximately 2,202 hectares approximately 13km northeast of Boston Bar, British Columbia.
New Energy Companies:
Sensor Technologies Inc. (CSE:SENS) - formerly Mooncor Oil and Gas Corp - is a leading solutions provider to various sectors including the oil and gas industry. With non-intrusive technologies including fiber-optic sensors and electric field mapping EFM systems. Sensor Technologies Corp is able to accurately measure changes that could negatively impact our client's operations. SENS F.O. sensors are a non-invasive tool for monitoring pipeline defects in real time. consist of non-intrusive sensors, monitor & software. SENS's EFM monitoring of isolated pit formation & growth using a non-permanent modular design based on electrical resistance measurements, monitoring locations may be placed hundreds of feet away from the sensors. Software operates in continuous or scheduled reporting modes. SENS's latest tech, is its leak detection system, for use in application such as Pipe sections at remote facilities Monitoring of Military, Scientific installations for corrosive liquids in harsh environments , in tank farms, pipe sections, Water leak detection in data centers & buildings.
New Nanotech Companies:
Sona Nanotech Inc. (CSE: SONA) is a nanotechnology life sciences firm that has developed two proprietary methods for the manufacture of rod-shaped gold nanoparticles. The principal business carried out and intended to be continued by Sona is the development and application of its proprietary technology for use in multiplex diagnostic testing platforms that will improve performance over existing tests in the market. Sona's gold nanorod particles are CTAB (cetyltrimethylammonium) free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. It is expected that Sona's gold nanotechnologies may be adapted for use in applications, as a safe and effective delivery system for multiple medical treatments, pending the approval of various regulatory boards including Health Canada and the FDA.
The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and sector trends from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto, technology including AI and IoT , mining ,sports biotech, water, renewable energy and more . Investorideas.com original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas #Potcasts#Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change Podcast.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer and disclosure info: https://www.investorideas.com/About/Disclaimer.asp.
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: https://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Learn more about our news, PR and social media services at Investorideas.com
Follow us on Twitter https://twitter.com/Investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
To sponsor one of our podcasts or columns or be a guest call us today!
Contact Investorideas.com
800-665-0411
